Prescription Drug Spending Surges on Weight Loss Meds

Prescription drug spending in the US is surging, with a record $915 billion spent in 2025, driven by blockbuster weight loss drugs like tirzepatide and semaglutide. These GLP-one drugs, such as Eli Lillys Zepbound and Novo Nordisks Wegovy, are dominating sales, with Zepbound raking in nearly $63 billion and Wegovy pulling in over $59 billion last year. Despite price cuts, demand is increasing as more employer plans cover these anti-obesity shots. Lilly and Novo are launching daily weight loss pills this year, and Medicare is introducing a bridge program to make them more accessible. Projections show another 10-12% jump this year, reshaping healthcare costs. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/4b41f32e503eadef